RespireRx Pharmaceuticals Inc. is a biopharmaceutical company which focused on the discovery and development of novel drug therapies for the treatment of sleep apnea, drug-induced respiratory depression and other brain- mediated breathing disorders. The company's drug platforms comprises of ampakines for positive allosteric modulators of AMPA glutamate receptors and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting as well as for anorexia. RespireRx Pharmaceuticals Inc. is based in Glen Rock, New Jersey.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-2.10M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 949.46M |
| Free Float | 474.45M |
| Market Capitalization | $1.42M |
| Average Volume (Last 20 Days) | 0.31M |
| Beta (Past 60 Months) | 0.43 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 50.03% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |